AETHLON MEDICAL INC
Close on Oct 19, 2026
- Market cap
- $1.99M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 10, 2026 | After market close | – | – | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | Jun 27, 2025 | During market hours | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 12, 2025 | After market close | – | $-0.13 | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | $-0.20 | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | $-0.34 | – |
| Q4 FY2024 Ended Mar 31, 2024 | Jun 27, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 14, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | – | – |
| Q1 FY2024 Ended Jun 30, 2023 | Aug 10, 2023 | After market close | – | – | – |
Press releases
Announcements Aethlon Medical filed with the SEC
PRESS RELEASE, ISSUED ON SEPTEMBER [16], 2026
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED SEPTEMBER 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Fiscal Q3 2026 Financial Results and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Pricing of a Private Placement and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aethlon Medical Announces Fiscal Q2 2025 Financial
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 4, 2025
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JUNE 26, 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Financial Results for the Fiscal Third Quarter Ended
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 19, 2024
Other events · EX-99.1 to Form 8-K
Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 12, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JUNE 27, 2024
Results of operations · EX-99.1 to Form 8-K
SAN DIEGO, May 15, 2024 -- Aethlon Medical, Inc.
Other events · EX-99.1 to Form 8-K
Reports Positive Results From an In Vitro Binding Study of Its
Other events · EX-99.1 to Form 8-K
COMPANY PRESENTATION, DATED APRIL 2024
Other events · EX-99.1 to Form 8-K
Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aethlon Announces Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Announces Fiscal First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Aethlon Medical Announces Fiscal Year End Financial
Results of operations · EX-99.1 to Form 8-K
Aethlon Medical Announces Third Quarter Financial
Results of operations · EX-99.1 to Form 8-K
Aethlon Medical Announces Second Quarter Financial
Results of operations · EX-99.1 to Form 8-K
by the Board of Directors: February 6, 2020
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
in this Exhibit 99.2, unless the context indicates otherwise, references to “the Company,” “we,” “us,”
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.2 to Form 8-K
Announces First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AETHLON MEDICAL ANNOUNCES FISCAL YEAR END FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Results of operations · EX-99.1 to Form 8-K
Aethlon Medical Announces Third Quarter Financial
Results of operations · EX-99.1 to Form 8-K
Announces Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K